Statin-based therapy for primary and secondary prevention of ischemic stroke: A meta-analysis and critical overview
Date
2020Language
en
Keyword
Abstract
Background and aims: To reassess the effect of statin-based lipid-lowering therapy on ischemic stroke in primary and secondary prevention trials with regard to achieved levels of low-density lipoprotein-cholesterol in view of the availability of novel potent hypolipidemic agents. Methods: English literature was searched (up to November 2018) for publications restricted to trials with a minimum enrolment of 1000 and 500 subjects for primary and secondary prevention, respectively, meeting the following criteria: adult population, randomized controlled design, and recorded outcome data on ischemic stroke events. Data were meta-analyzed and curve-estimation procedure was applied to estimate regression statistics and produce related plots. Results: Four primary prevention trials and four secondary prevention trials fulfilled the eligibility criteria. Lipid-lowering therapy was associated with a lower risk of ischemic stroke in primary (risk ratio, RR 0.70, 95% confidence interval, CI, 0.60–0.82; p < 0.001) and in the secondary prevention setting (RR 0.80, 95% CI 0.70–0.90; p < 0.001). Curve-estimation procedure revealed a linear relationship between the absolute risk reduction of ischemic stroke and active treatment-achieved low-density lipoprotein-cholesterol levels in secondary prevention (adjusted R-square 0.90) in support of “the lower the better” hypothesis for stroke survivors. On the other hand, the cubic model followed the observed data well in primary prevention (adjusted R-square 0.98), indicating greater absolute risk reduction in high-risk cardiovascular disease-free individuals. Conclusions: Statin-based lipid-lowering is effective both for primary and secondary prevention of ischemic stroke. Most benefit derives from targeting disease-free individuals at high cardiovascular risk, and by achieving low treatment targets for low-density lipoprotein-cholesterol in stroke survivors. © 2019 World Stroke Organization.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Embolic stroke of undetermined source and atrial cardiopathy: Towards a personalized antithrombotic strategy for secondary stroke prevention
Ntaios G., Korompoki E. (2022)[No abstract available] -
Anticoagulation for stroke prevention after embolic stroke of undetermined source of presumably cardiac source: The sail to Ithaca
Sagris D., Ntaios G. (2022)[No abstract available] -
Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial
Hart R.G., Sharma M., Mundl H., Shoamanesh A., Kasner S.E., Berkowitz S.D., Pare G., Kirsch B., Pogue J., Pater C., Peters G., Davalos A., Lang W., Wang Y., Wang Y., Cunha L., Eckstein J., Tatlisumak T., Shamalov N., Mikulik R., Lavados P., Hankey G.J., Czlonkowska A., Toni D., Ameriso S.F., Gagliardi R.J., Amarenco P., Bereczki D., Uchiyama S., Lindgren A., Endres M., Brouns R., Yoon B.-W., Ntaios G., Veltkamp R., Muir K.W., Ozturk S., Arauz A., Bornstein N., Bryer A., O’Donnell M.J., Weitz J., Peacock F., Themeles E., Connolly S.J. (2016)Background: Embolic strokes of undetermined source comprise up to 20% of ischemic strokes. The stroke recurrence rate is substantial with aspirin, widely used for secondary prevention. The New Approach riVaroxaban Inhibition ...